Keywords: Merck & Co, Fosamax, State court trial, Osteonecrosis, Bisphosphonates

Merck & Co wins first Fosamax state court trial; new study finds low osteonecrosis risk for bisphosphonates

Article | 15 February 2011

Print This

US drugs giant Merck & Co (NYSE: MRK) said yesterday that a state court jury in New Jersey found in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in